Study #2024-1159
Extending outcomes for pancreas cancer patients with nominal oligometastatic disease (EXPAND): A randomized phase III trial
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreas Cancer;Oligometastatic
Study phase:
Phase III
Physician name:
Ethan Ludmir
Department:
Radiation Oncology
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.